| 11/16/2026 8:56 PM | ADAR1 Capital Management, LLC (1940272) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G | |
| 11/13/2026 8:22 PM | Coastlands Capital LP (2068530) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G/A | |
| 11/12/2026 8:01 AM | Adage Capital Management, L.P. (1535978) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G | |
| 11/10/2026 6:45 AM | Xilio Therapeutics (1840233) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 11/10/2026 6:35 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/10/2026 6:40 AM | Xilio Therapeutics (1840233) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/02/2026 3:31 PM | Houvras Yariv (2154870) Reporting Xilio Therapeutics (1840233) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 10/02/2026 3:33 PM | Houvras Yariv (2154870) Reporting Xilio Therapeutics (1840233) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2026 11:01 AM | STEMPOINT CAPITAL LP (1952142) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G/A | |
| 08/12/2026 6:40 AM | Xilio Therapeutics (1840233) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/12/2026 6:45 AM | Xilio Therapeutics (1840233) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
Get the Latest News and Ratings for XLO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/12/2026 6:35 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/12/2026 3:05 PM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/31/2026 11:15 PM | Xilio Therapeutics (1840233) Filer | Form EFFECT | |
| 05/27/2026 4:30 PM | Xilio Therapeutics (1840233) Filer | Form S-3/A | |
| 05/15/2026 7:06 AM | Sirenia Capital Management LP (2115022) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G | |
| 05/12/2026 6:40 AM | Xilio Therapeutics (1840233) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/12/2026 6:48 AM | Xilio Therapeutics (1840233) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 05/12/2026 6:35 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/28/2026 4:02 PM | Xilio Therapeutics (1840233) Filer | Form DEF 14A | |
| 04/28/2026 4:07 PM | Xilio Therapeutics (1840233) Filer | Form ARS | |
| 04/16/2026 4:11 PM | Blanchard Cheryl R (1326530) Reporting Xilio Therapeutics (1840233) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/16/2026 4:12 PM | Blanchard Cheryl R (1326530) Reporting Xilio Therapeutics (1840233) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/16/2026 6:35 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/23/2026 6:47 AM | Xilio Therapeutics (1840233) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/23/2026 6:40 AM | Xilio Therapeutics (1840233) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/23/2026 6:33 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/12/2026 7:34 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/09/2026 7:00 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/24/2026 6:30 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/17/2026 4:31 PM | GILEAD SCIENCES, INC. (882095) Reporting Xilio Therapeutics (1840233) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 3:30 PM | Bain Capital Life Sciences Fund II, L.P. (1773187) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G/A | |
| 02/13/2026 4:31 PM | Frazier Life Sciences Public Fund, L.P. (1863769) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G/A | |
| 02/12/2026 3:49 PM | Xilio Therapeutics (1840233) Filer | Form 424B5 | |
| 02/11/2026 4:16 PM | Xilio Therapeutics (1840233) Filer | Form 424B5 | |
| 01/26/2026 6:30 AM | Xilio Therapeutics (1840233) Filer | Form DEF 14A | |
| 01/08/2026 7:42 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 7:30 AM | Xilio Therapeutics (1840233) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/11/2025 4:55 PM | Coastlands Capital LP (2068530) Filed by Xilio Therapeutics (1840233) Subject | Form SCHEDULE 13G | |
| 12/01/2025 3:36 PM | GILEAD SCIENCES, INC. (882095) Reporting Xilio Therapeutics (1840233) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/25/2025 3:16 PM | Xilio Therapeutics (1840233) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
Top Trader Reveals Stunning Black Friday Deal (Ad) Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7.
Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before.
There are no strings attached, just a steep Black Friday discount on a tool built for traders. Get the Snapback Indicator for just $7 in the Black Friday sale today. |